Previous 10 | Next 10 |
3 Biotech Penny Stocks to Watch This Month As we head toward the middle of January, there are plenty of penny stocks that are showing potential. This week got off to an interesting start, with most blue-chip stocks trading lower. However, as the day progressed we watched many stocks...
H.C. Wainwright points out that BioLineRx ([[BLRX]] -16.3%) shares selloff following positive data from COMBAT study, is a "classic example of 'sell on the news' following a strong stock run up. Over one year shares have gained ~52% while YTD shares have increased ...
Gainers: Nxt-ID (NXTD) +50%.Diginex (EQOS) +48%.Aethlon Medical (AEMD) +40%.MIND Technology (MIND) +27%.Aclaris Therapeutics (ACRS) +24%.Tilray (TLRY) +23%.MiMedx Group (MDXG) +22%.Amyris (AMRS) +21%.Drive Shack (DS) +20%.Marathon Patent Group (MARA) +19%.Losers: Concord Medical Services...
Gainers: Aethlon Medical (AEMD) +47%. Aclaris Therapeutics (ACRS) +32%. Tilray (TLRY) +23%. MiMedx Group (MDXG) +23%. Sio Gene Therapies (SIOX) +21%.Losers: Concord Medical Services Holdings (CCM) -43%. BioLineRx (BLRX) -30%. vTv Therapeutics (VTVT) -22%. Sensus Healthcare (SRTS) -1...
Concord Medical Services Holdings (CCM) -40%.vTv Therapeutics (VTVT) -33% after azeliragon flunks in mid-stage alzheimer’s and diabetes study.BioLineRx (BLRX) -27% despite promising motixafortide data in pancreatic cancer.NanoVibronix (NAOV) -17%.Galapagos (GLPG)...
BioLineRx (BLRX) gains 22% premarket after announcing results from its COMBAT/KEYNOTE-202 clinical study evaluating motixafortide (BL-8040) in combination with Merck's (MRK) KEYTRUDA (pembrolizumab) and chemotherapy in patients with second-line stage IV pancreatic ductal adenoc...
BioLineRx Announces Final Results from Phase 2a COMBAT/KEYNOTE-202 Triple Combination Study of Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC) TEL AVIV, Israel , Dec. 16, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinic...
Prevail Therapeutics (PRVL) +84% on being acquired by Lilly for ~$1.04B.OncoCyte Corporation (OCX) +63% after company enters agreement with Burning Rock Biotech.Anavex Life Sciences (AVXL) +40% as it's blarcamesine successful in mid-stage rett syndrome study.Mid-Con Energy Part...
Gainers: BioCardia (BCDA) +102%.Arvinas (ARVN) +91%.Rubius Therapeutics (RUBY) +56%.Veru (VERU) +48%.AnPac Bio-Medical Science (ANPC) +45%.Homology Medicines (FIXX) +32%.ReneSola (SOL) +32%.Alexion Pharmaceuticals (ALXN) +31%.BioLineRx (BLRX) +30%.Big Rock Partners Acquisition (BRPA...
3 Penny Stocks Trading Higher This Week Most traders will start with a list of penny stocks to watch before jumping into a trade. The simple reason behind it is that there are different strategies involving numerous attributes. Some traders look for fast-moving stocks to scalp while...
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Ltd. Company Name:
BLRX Stock Symbol:
NASDAQ Market:
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024 PR Newswire - Presentation Today, Monday, May 6, 2024 in Atlanta , Geo...
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting PR Newswire TEL AVIV, Israel , April 17, 2024 /PRNewswire/ --...
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement PR Newswire - Proceeds to be used to further accelerate uptake of APHEXDA® in stem cell mobilization, life-cycle expansion activities in sic...